AT1R-Antibody ELISA
Transplantation Rejection Risk, Systemic Sclerosis
CommercialActive
Key Facts
Indication
Transplantation Rejection Risk, Systemic Sclerosis
Phase
Commercial
Status
Active
Company
About CellTrend
CellTrend is a niche biotechnology firm with a dual business model combining contract research services and proprietary diagnostic development. Its core expertise lies in cell-based bioassays and ELISA-based detection of autoantibodies, particularly against G-protein coupled receptors (GPCRs), with a flagship patented test for Angiotensin-II-Receptor-1 antibodies. The company is strategically positioned in the growing field of post-infectious and autoimmune disease diagnostics, especially for conditions like Long COVID, POTS, and ME/CFS, while serving pharmaceutical clients through its CRO services.
View full company profile